Burkitt Lymphoma Research Paper

Non-Hodgkin’s lymphoma is one of the most common types of cancers in the United States that affect mostly older adults. The American Cancer Society estimates that 72,580 people in the Unites States will be diagnosed with the disease just in the year 2016 alone. Of that number, there are about 20,150 people expected to die from the disease. There is also a 2% chance of people in the United States developing the disease (American cancer society, n.d.). There have been many researches done about the

The HH514-16 Burkitt lymphoma B cell is a cell line used that is infected with the Epstein-Barr Virus.  Cells are grown using RPMI 1640 medium containing 8% fetal bovine serum; a supplement contain low level of antibodies and growth factors.  Quality and quantity of the cells

will be a reflection on the process I undertook from researching to writing this report and how I have developed as a learner. Background Professor Suzanne Cory is an Australian molecular biologist who is internationally renowned for her pivotal research in immunology and cancer (Tattam, 2000). Currently, she is the immediate past president of the Australian Academy of Science and an Honorary Distinguished Professorial Fellow in the Molecular Genetics of Cancer Division of the Walter and Eliza Hall

Introduction The incidence of skin cancer accounts for nearly one third of all cancers in diagnosed the United States. While melanoma affects roughly 4 percent of skin cancers, it accounts for nearly 80 percent of deaths associated with skin cancer. Unlike other cancers, melanoma is one of the few where the incidence is increasing over time. Without early detection, aggressive local growth and distant metastasis become likely outcomes that are often resistant to conventional forms of therapy1-3